| Review Article | 
|  |
IJMDC. 2020; 4(11): 1980-1983 Role of serotonin reuptake inhibitor (SSRI) therapies as a therapeutic option for irritable bowel syndrome: a brief reviewIbrahim Mahmoud Ajwah, Waad Maher Alqulayti, Maram Salim Algrani, Maryam Talal Altuwayjiri, Sahar Yahya S Alatawi, Yazeed Saeed M Alqahtani, Razan Kamel Albalawi, Hadeel Ahmed Almutairi, Yassmeen Hmoud Alblowi, Alaa Sulaiman Almehmadi, Muflih Abdullah Saed Albalawi, Abdulmajeed Faisal A Albalawi, Waleed Khaled Alshehri, Maram Ali Jarallah, Wejdan Saleem Aljohani, Rama Osama Abu Alez. Abstract | | | | Psychological factors are considered very important to be associated with the development of irritable bowel syndrome (IBS). Trials were suggesting that antidepressant therapy may be useful for patients for symptomatic relief in IBS patients. This study is aimed to summarize the role of selective serotonin reuptake inhibitor (SSRI) therapies for IBS. PubMed, Google Scholar, and EBSCO databases were used to systematically search for relevant articles. The terms antidepressant, functional bowel disorders, and irritable bowel syndrome« were used. Among 107 articles, six randomized controlled trials fulfilled the inclusion criteria. In these studies, the efficacy of selective SSRIs was analyzed in IBS. Different interventions were used although, in most studies, their effect on IBSs global symptom relief as a primary outcome was investigated. In IBS patients, SSRI was proven to be effective in pain-relieving and symptom improvement. Although clinical practice guidelines suggest the use of SSRI, clinicians should also consider patients acceptance for it.
Key words: Functional bowel disorders, systematic review, therapies
|
|
|
|
